Zoe Price

Research Interests

Cancer Cell Biology Cancer Biology and Clinical Oncology Biochemistry and Cell Biology Biochemistry & Molecular Biology Chemotherapy

Dr Zoe Price

Research Associate

Centre for Cancer Biology

College of Health

Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.

Dr Zoe Price is an early career researcher in the Gene Regulation in Cancer research group at the Centre for Cancer Biology. Her research focuses on alternative splicing variants that drive prostate cancer progression and the development of castration-resistant prostate cancer. Her work aims to better understand the molecular mechanisms underpinning treatment resistance and to identify pro-tumourigenic splice isoforms with therapeutic potential.
 
Dr Price completed her PhD through a joint doctoral program between the University of Adelaide and Nagoya University. Her doctoral research investigated how different molecular weights of hyaluronan influence ovarian cancer stem cell signalling pathways and contribute to chemotherapy resistance. This work provided new insights into the role of extracellular matrix components in cancer progression and therapeutic response.

Date Position Institution name
2026 - ongoing Research Associate University of Adelaide
2025 - 2025 Research Associate University of South Australia
2023 - 2024 Research Assistant South Australian Health and Medical Research Institute
2018 - 2018 Research Assistant University of Adelaide

Date Institution name Country Title
2024 University of Adelaide Australia Jointly-Awarded PhD program between the University of Adelaide and Nagoya University
2017 - 2017 University of Adelaide Australia Honours Degree of Bachelor of Health and Medical Sciences
2013 - 2015 University of Adelaide Australia Bachelor of Biomedical Science (Biochemistry and Immunology and Virology)

Year Citation
2026 Lokman, N. A., Macpherson, A. M., Thompson, A. R., Price, Z. K., Goonetilleke, L., Condina, M. R., . . . Ricciardelli, C. (2026). Proteomics analysis of serum extracellular vesicle identifies UCHL1 as a potential therapeutic target for high grade serous ovarian cancer. British Journal of Cancer, 134(2), 195-207.
DOI Scopus1 WoS1 Europe PMC1
2025 Shah, M. V., Hung, K., Baranwal, A., Kutyna, M. M., Al-Kali, A., Toop, C., . . . Hiwase, D. K. (2025). Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations. Blood Advances, 9(13), 3370-3380.
DOI Scopus19 WoS18 Europe PMC17
2025 Price, Z. K., Lokman, N. A., Morrison, J., Mhlanga, S. N., Sugiyama, M., Koya, Y., . . . Ricciardelli, C. (2025). Identification of Sphingosine Kinase 1 as a Novel Protein Regulated by High Molecular Weight Hyaluronan in Ovarian Cancer.. J Cell Mol Med, 29(9), e70574.
DOI
2025 Noye, T. M., Mittal, P., Price, Z. K., Fewster, A., Williams, G., Pukala, T. L., . . . Ricciardelli, C. (2025). Identification of Proteins Associated with Ovarian Cancer Chemotherapy Resistance Using MALDI-MSI. International Journal of Molecular Sciences, 26(12), 5893.
DOI Scopus1 WoS1
2025 Khetan, R., Lokman, N. A., Eldi, P., Price, Z. K., Oehler, M. K., Brooks, D. A., . . . Albrecht, H. (2025). Protease-Activated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer. International Journal of Molecular Sciences, 26(17), 8529.
DOI Scopus3 WoS3 Europe PMC3
2023 Varricchio, A., Khan, S., Price, Z. K., Davis, R. A., Ramesh, S. A., & Yool, A. J. (2023). Pharmacological Inhibition of Membrane Signaling Mechanisms Reduces the Invasiveness of U87-MG and U251-MG Glioblastoma Cells In Vitro. Cancers, 15(4), 1-20.
DOI Scopus19 WoS18 Europe PMC17
2023 Price, Z. K., Lokman, N. A., Sugiyama, M., Koya, Y., Yoshihara, M., Oehler, M. K., . . . Ricciardelli, C. (2023). Disabled-2: a protein up-regulated by high molecular weight hyaluronan has both tumor promoting and tumor suppressor roles in ovarian cancer. Cellular and Molecular Life Sciences, 80(11), 1-18.
DOI Scopus8 WoS7 Europe PMC7
2022 Leung, D., Price, Z. K., Lokman, N. A., Wang, W., Goonetilleke, L., Kadife, E., . . . Ahmed, N. (2022). Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial–mesenchymal transition interlinked with reprogrammed metabolism. Journal of Translational Medicine, 20(1), 556-1-556-23.
DOI Scopus33 WoS37 Europe PMC31
2022 Price, Z. K., Lokman, N. A., Yoshihara, M., Kajiyama, H., Oehler, M. K., & Ricciardelli, C. (2022). Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways. International Journal of Molecular Sciences, 24(1), 696.
DOI Scopus23 WoS22 Europe PMC21
2019 Lokman, N. A., Price, Z. K., Hawkins, E. K., Macpherson, A. M., Oehler, M. K., & Ricciardelli, C. (2019). 4-Methylumbelliferone inhibits cancer stem cell activation and overcomes chemoresistance in ovarian cancer. Cancers, 11(8), 1-18.
DOI Scopus50 WoS44 Europe PMC40
2019 Mittal, P., Price, Z. K., Lokman, N. A., Ricciardelli, C., Oehler, M. K., Klingler-Hoffmann, M., & Hoffmann, P. (2019). Matrix Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI MSI) for monitoring of drug response in primary cancer spheroids. Proteomics, 19(21 - 22), e1900146-1-e1900146-4.
DOI Scopus23 WoS21 Europe PMC18
2018 Price, Z., Lokman, N., & Ricciardelli, C. (2018). Differing roles of hyaluronan molecular weight on cancer cell behavior and chemotherapy resistance. Cancers, 10(12), 482-1-482-21.
DOI Scopus87 WoS81 Europe PMC70

Year Citation
2025 Khetan, R., Lokman, N. A., Eldi, P., Price, Z. K., Oehler, M. K., Brooks, D. A., . . . Albrecht, H. (2025). Protease-activated receptor F2R/PAR1 is a potential target for new diagnostic/prognostic and treatment applications for patients with ovarian cancer. Poster session presented at the meeting of CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
DOI
2024 Wang, W. J., Bandara, V., Lokman, N. A., Price, Z. K. K., Noye, T. M., Napoli, S., . . . Ricciardelli, C. (2024). CAR-T cells targeting LGR5: An effective treatment for chemotherapy resistant ovarian cancer. Poster session presented at the meeting of Proceedings of the American Association for Cancer Research Annual Meeting (AACR, 2024) as published in Cancer Research. San Diego, California: American Association for Cancer Research.
DOI WoS1
2024 Shah, M., Hung, K., Baranwal, A., Price, Z., Al-Kali, A., Toop, C., . . . Hiwase, D. (2024). The 66th ASH Annual Meeting Abstract Abstracts. Poster session presented at the meeting of BLOOD. ELSEVIER.
2024 Hung, K., Al-Kali, A., Toop, C., Patnaik, M. M., Price, Z., Kourelis, T., . . . Shah, M. (2024). <i>TP53</i>-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors. Poster session presented at the meeting of BLOOD. FL, Orlando: ELSEVIER.
DOI WoS2
2024 Hiwase, D., Price, Z., Kok, C. H., Kutyna, M., Singhal, D., Shanmuganathan, N., . . . Scott, H. S. (2024). Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure. Poster session presented at the meeting of BLOOD. FL, Orlando: ELSEVIER.
DOI

Date Role Research Topic Program Degree Type Student Load Student Name
2026 Co-Supervisor Discovery of alternative splicing pathways that promote lethal castrate resistant prostate cancer Doctor of Philosophy Doctorate Full Time Josefanny Josefanny
2026 Co-Supervisor Discovery of alternative splicing events that drive lethal castrate resistant prostate cancer Doctor of Philosophy Doctorate Full Time Miss Hongyu Li

Connect With Me

External Profiles

Other Links